Results 191 to 200 of about 236,434 (328)

A New Synthesis of Lead Azide [PDF]

open access: bronze, 1963
Bruno Reitzner, RALPH P. MANNO
openalex   +1 more source

Enhancing Chemotherapy‐Related Immune Responses via Bioorthogonal Metabolic Engineering‐Driven Tumor Exosomes Elimination

open access: yesAdvanced Science, EarlyView.
In this work, a novel strategy named bioorthogonal reaction‐driven exosome elimination (Biordee) strategy was developed to inhibit chemotherapy‐associated breast cancer metastasis and enhance the immune response. Biordee possessed the capacity of in‐situ editing tumor‐derived exosomes (TExo) with IgG Fc and promoted macrophage phagocytosis of ...
Wentao Zhang   +6 more
wiley   +1 more source

INHIBITION OF CATALASE IN PERFUSED RAT LIVER BY SODIUM AZIDE* [PDF]

open access: bronze, 1969
Ronald G. Thurman, Britton Chance
openalex   +1 more source

Nature‐Inspired Nanostructures from Multiple‐Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor‐Targeted Nanomedicine

open access: yesAdvanced Science, EarlyView.
Naturally derived biomembrane nanostructures by mimicking evolutionarily optimized biological architectures could effectively suppress tumor growth and have emerged as a compelling strategy in translational biomedicine. This review provides a systematic overview of rational design and underlying antitumor therapeutic mechanisms of mammalian cells ...
Xiaodan Wei   +10 more
wiley   +1 more source

Introducing Azide into Fully Nitrated Systems: Charge Mutations toward Advanced Initiators. [PDF]

open access: yesJACS Au
Jiang Z   +9 more
europepmc   +1 more source

Low-Frequency Molecular Motions in Ammonium Azide [PDF]

open access: bronze, 1966
Henri Boutin   +2 more
openalex   +1 more source

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study demonstrates that engineering CAR T cells to express CXCL13 enhances their antitumor efficacy and significantly improves responsiveness to PD‐1 immune checkpoint blockade. CXCL13 promotes T cell persistence, and resistance to early exhaustion via the AKT‐mTOR pathway.
Yang Zhou   +15 more
wiley   +1 more source

Developing a new cleavable crosslinker reagent for in-cell crosslinking. [PDF]

open access: yesCommun Chem
Müller F   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy